ASCO20 Virtual

Date: May 29 – 31, 2020
Location: Virtual

 

In collaboration with Northwestern University and Peking University Cancer Hospital, we are presenting a poster at the American Society of Clinical Oncology Virtual Scientific Program.

This study demonstrates that PredicineCARE blood-based ctDNA effectively detected the key mutations in HR+ metastatic breast cancer patients in US and China.  Genomic landscape of patients with HR+ MBC at time of first recurrence or de-novo metastatic diagnosis in the US and China were compared and analyzed using PredicineCARE blood-based testing and notable differences in somatic variants was observed in the two cohorts.

Make sure to check out our poster presentation and our virtual exhibition to schedule a meeting with us!

Leave a Reply

10 − 1 =